“Absolute Flood” of ADCs and Key Data Lead to “Good Challenges” in EGFR-Mutated NSCLC

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome Julia Rotow, MD to the conversation.

“I think we’ve been very lucky, in the world of EGFR-mutated lung cancer, that it has gotten so complicated,” explains Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at the Dana-Farber Cancer Institute in Boston. Dr. Rotow explains how key data from the HARMONi, COMPEL, and MARIPOSA-2 studies and a wave of new treatment options on the horizon have led to “good challenges” in non-small cell lung cancer care.